We are live on ! Find out more
ORIA

Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA

Delisted

ORIA was delisted on the 28th of April, 2023.

Back to rankings

49 hedge funds and large institutions have $145M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less capital invested

Capital invested by funds: $149M → $145M (-$3.88M)

4% less funds holding

Funds holding: 51 → 49 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

Holders
49
Holders Change
-2
Holders Change %
-3.92%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
12
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WCMNY
Westchester Capital Management (New York)
New York
+$9.41M
2
AC
Aristeia Capital
Connecticut
+$9.17M
3
CCA
Castle Creek Arbitrage
Colorado
+$5.38M
4
MC
Meteora Capital
Florida
+$3.72M
5
UOC
UBS O'Connor
Illinois
+$2.39M

Top Sellers

Rank Fund Capital Flow
1
KL
KIM LLC
Kansas
-$8.06M
2
CSS
Cubist Systematic Strategies
Connecticut
-$6.32M
3
Millennium Management
Millennium Management
New York
-$6.29M
4
6CM
683 Capital Management
New York
-$5.08M
5
FTCM
First Trust Capital Management
Illinois
-$2.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Segantii Capital Management
Hong Kong
$1.54M – – –
ACA
27
Arena Capital Advisors
California
$1.45M – – –
SCM
28
Shaolin Capital Management
Florida
$1.25M -$1.27M -125,000 -51%
LP
29
LMR Partners
United Kingdom
$1.08M – – –
WAM
30
Weiss Asset Management
Massachusetts
$1.02M -$10.2K -1,005 -1%
DCM
31
Dupont Capital Management
Delaware
$1.02M – – –
CH
32
CVI Holdings
Delaware
$1.02M -$19.1K -1,877 -2%
MSU
33
Mizuho Securities USA
New York
$1.01M +$1.02M +100,000 New
SSA
34
Schonfeld Strategic Advisors
New York
$972K -$25.5K -2,513 -3%
WA
35
Whitebox Advisors
Minnesota
$767K – – –
Marshall Wace
36
Marshall Wace
United Kingdom
$741K -$2.27M -223,411 -76%
VF
37
Virtu Financial
New York
$631K +$268K +26,433 +75%
MMRF
38
Michelson Medical Research Foundation
California
$519K – – –
COPPSERS
39
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$512K – – –
LA
40
Linden Advisors
New York
$428K – – –
Bank of Nova Scotia
41
Bank of Nova Scotia
Ontario, Canada
$409K – – –
HighTower Advisors
42
HighTower Advisors
Illinois
$283K – – –
PAMP
43
Polar Asset Management Partners
Ontario, Canada
$275K – – –
HF
44
HRT Financial
New York
$204K – – –
GAM
45
Gritstone Asset Management
Maryland
$167K +$166K +16,330 New
CC
46
Centiva Capital
New York
$108K – – –
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$102K -$115K -11,357 -53%
CS
48
Clear Street
New York
$1.23K +$1.16K +114 +1,900%
EC
49
Elequin Capital
New York
$51 +$51 +5 New
KL
50
KIM LLC
Kansas
– -$8.06M -800,000 Closed
1
2
3

ORIA Hedge Fund Activity: Q1 2023 in Review

49 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q1 2023, worth a combined $145M — down 2.6% from $149M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ORIA and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 7 added.

The largest buyer was Westchester Capital Management (New York), adding an estimated $9.41M. The largest seller was KIM LLC, exiting entirely with an estimated $8.06M sold.

  • 49 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q1 2023, down from 51 in Q4 2022.
  • Funds reported $145M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q1 2023, down 2.6% quarter-over-quarter.
  • 7 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q1 2023 and 9 closed out, a net change of -2 holders.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q1 2023 was Westchester Capital Management (New York), an estimated $9.41M added.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q1 2023 was KIM LLC, an estimated $8.06M sold.

Based on aggregated 13F filings for Q1 2023.